logo
logo

Cardiosense, Inc., Completes $15.1 Million Series A Financing To Advance Artificial Intelligence Platform For Heart Disease

Dec 08, 2022•over 2 years ago

Amount Raised

$15.1 Million

Round Type

series a

ChicagoOther

Investors

Unity Point Health VenturesOsf VenturesLaerdal Million Lives FundHatteras Venture PartnersBroadview Ventures

Description

Cardiosense, Inc., a Chicago-based digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.

Company Information

Company

Cardiosense

Location

400 N. ABERDEEN ST.

Chicago, Illinois, United States

About

Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes. For more information, visit: www.cardiosense.com.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People